Literature DB >> 32453693

Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".

Marco Marietta1, Armando Tripodi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32453693      PMCID： PMC7250695          DOI： 10.2450/2020.0116-20

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  4 in total

1.  COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).

Authors:  Marco Marietta; Walter Ageno; Andrea Artoni; Erica De Candia; Paolo Gresele; Marina Marchetti; Rossella Marcucci; Armando Tripodi
Journal:  Blood Transfus       Date:  2020-04-08       Impact factor: 3.443

2.  Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence.

Authors:  Julien Poissy; Julien Goutay; Morgan Caplan; Erika Parmentier; Thibault Duburcq; Fanny Lassalle; Emmanuelle Jeanpierre; Antoine Rauch; Julien Labreuche; Sophie Susen
Journal:  Circulation       Date:  2020-04-24       Impact factor: 29.690

3.  Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.

Authors:  Marco Cattaneo; Nuccia Morici
Journal:  Blood Transfus       Date:  2020-05       Impact factor: 3.443

4.  Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis.

Authors:  Mauro Panigada; Nicola Bottino; Paola Tagliabue; Giacomo Grasselli; Cristina Novembrino; Veena Chantarangkul; Antonio Pesenti; Flora Peyvandi; Armando Tripodi
Journal:  J Thromb Haemost       Date:  2020-06-24       Impact factor: 5.824
  4 in total
  1 in total

1.  Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate.

Authors:  Pierpaolo Di Micco; Vincenzo Russo; Corrado Lodigiani
Journal:  Medicina (Kaunas)       Date:  2020-09-27       Impact factor: 2.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.